Resonance Health has achieved another milestone in its provision of MRI-based measurement services to the global clinical community, having now provided the Company’s lead product, FerriScan® to more than 30,000 patients worldwide.
Reaching this milestone has earned Resonance Health the endorsement of a major international patient advocacy organisation, Thalassemia International Federation, (TIF) which aims to improve control of the disease and ensure equitable access to care for sufferers worldwide.
Panos Englezos, President of TIF said
“On behalf of the Board of Directors of Thalassaemia International Federation (TIF) I hereby express our sincere congratulations to Resonance Health Ltd for the achievement of providing 30,000 FerriScans worldwide, supporting in this way the global effort of our Federation to best practice iron load monitoring in patients with haemoglobin disorders.
We are indeed very proud to acknowledge the tremendous contribution that the 30.000 FerriScan have had to the global patients’ community. Currently FerriScan is the only FDA/EMA approved technology for the specific and accurate measurement of iron in the liver.”
FerriScan is now available in more than 30 countries, from the USA and UK to China, Eastern Europe and Africa.
Chairman Dr Martin Blake commented
“We are very proud to have won the recognition and support of such an important organisation as TIF through our adherence to scientific rigour and complete quality management. TIF’s efforts and interests are focussed on improving patient outcomes and they are influential in guiding clinical best practice worldwide in the management of these diseases.”